# Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation

> **NCT04942886** · NA · ENROLLING_BY_INVITATION · sponsor: **Seoul St. Mary's Hospital** · enrollment: 226 (estimated)

## Conditions studied

- Hepatitis B Reactivation
- Hematopoietic Stem Cell Transplantation
- Antiviral Drug
- HBV

## Interventions

- **DRUG:** Baracle Tab.®

## Key facts

- **NCT ID:** NCT04942886
- **Lead sponsor:** Seoul St. Mary's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-08-21
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04942886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04942886, "Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04942886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*